Merck (MRK.US) — market event timeline
NashNova tracks 4 market events mentioning Merck (MRK.US) between 2026-06-17 and 2026-06-30, each with a dated one-line analysis of how the event relates to the asset.
- Bipartisan U.S. House Investigation Targets Merck and AbbVie Over Clinical Trial Safety Risks in China
Directly targeted by the event; congressional investigation into its clinical trials in China may force adjustments to its China trial operations and increase compliance costs.
- FDA Approves Gilead's Trodelvy for First-Line Treatment of Triple-Negative Breast Cancer
Keytruda's approval in combination with Trodelvy for first-line TNBC adds a new combination therapy scenario, expanding Keytruda's prescription volume.
- Pfizer's Lung Cancer Drug Sigvotatug Vedotin Misses Primary Endpoint in Phase 3 Trial
Keytruda is being advanced in late-stage trials in combination with this drug; changes in trial prospects directly affect expectations for the combination therapy.
- FDA Briefing Reveals No Major Deficiencies, Moderna Stock Surges 9.1% in Single Day
Co-developing a personalized mRNA cancer vaccine with Moderna; regulatory validation of Moderna's platform indirectly benefits expectations for the collaborative pipeline.
For research and information only — not investment advice.